ESC 365 - ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients

ESC Professional Premium Access

ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients

Session: Late-breaking science on pharmacology

Topic: Lipid-Lowering Agents

Speaker: Professor R. Wright (Rochester, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor R Scott Wright

Mayo Clinic, Rochester (United States of America)

4 presentations

3 followers

3 more presentations in this session

Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)

Speaker: Professor S. Nicholls (Melbourne, AU)

LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

Speaker: Professor F. Raal (Johannesburg, ZA)

REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia

Speaker: Professor J. Ge (Shanghai, CN)

Access the full session

Late-breaking science on pharmacology

Speakers: Professor R. Wright, Professor S. Nicholls, Professor F. Raal, Professor J. Ge

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources